临床与病理视角解读精准医学时代下免疫治疗靶标现状  

Current status of biomarkers for immunotherapy:Updated approaches from recent clinical and pathological insights

作　　者：陈誉[1,2,3] 林晶 郭增清[1,2,3] 陈刚 郑雄伟 CHEN Yu;LIN Jing;GUO Zengqing;CHEN Gang;ZHENG Xiongwei(Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China)

机构地区：[1]福建医科大学附属肿瘤医院福建省肿瘤医院肿瘤内科,福州350014 [2]福建医科大学附属肿瘤医院福建省肿瘤医院肿瘤生物免疫治疗中心,350014 [3]福建省转化医学重点实验室,350014 [4]福建医科大学附属肿瘤医院福建省肿瘤医院病理科,350014

出　　处：《临床肿瘤学杂志》2019年第3期262-266,共5页Chinese Clinical Oncology

基　　金：国家自然科学基金资助项目(U1705282);福建省自然科学基金面上资助项目(2017J01259;2018J01267);福建省卫生计生委课题基金资助项目(2015-CX-7;2018-ZQN-13;2016-1-11;2018-1-13);福建省科技创新联合资金资助项目(2017Y9077);福建省肿瘤精准医疗产业技术创新研究院资助项目(2018Y2003)

摘　　要：近年来,以免疫检查点抑制剂为核心的肿瘤免疫治疗在实体瘤中取得了重大进展,如何筛选优势人群以及如何优化免疫联合策略,是现阶段免疫治疗的两大主题。现代病理学快速发展为实现精准免疫治疗提供了坚实的基础,本文将从临床以及病理视角解读目前免疫治疗的相关靶标,包括程序性死亡分子配体1、错配修复蛋白、肿瘤突变负荷以及组织/液态检测如何应用。In recent years, significant progress has been made in tumor immunotherapy with immuno-checkpoint inhibitors as its core in solid tumors. How to screen the dominant population and how to optimize the immune combination strategy are the two main themes of immunotherapy at present. The rapid development of modern pathology provides a solid foundation for the realization of precise immunotherapy. This article will interpret the current immunotherapy-related targets from the clinical and pathological perspectives, including programmed death-ligand 1, mismatch repair protein, tumor mutation load and how to apply tissue/liquid detection.

关 键 词：肿瘤 免疫治疗 程序性死亡分子1/程序性死亡分子配体1(PD-1/PD-L1)抑制剂 肿瘤突变负荷 错配修复蛋白 微卫星不稳定 

分 类 号：R730[医药卫生—肿瘤]